CARB-X is a global accelerator dedicated to advancing new solutions to combat antibiotic-resistant bacteria. The program supports companies developing novel antibiotics, diagnostics, vaccines, and other technologies aimed at fighting drug-resistant infections—one of the world’s most urgent public health challenges.
Through substantial funding opportunities, expert mentorship, and access to specialized resources, CARB-X helps early-stage innovators accelerate the development of breakthrough treatments and technologies.
Since its launch in 2016, CARB-X has invested $396 million into pioneering antimicrobial projects, backing companies such as HelixBind, Proteus, and T2 Biosystems. The program continues to play a central role in strengthening the global pipeline of solutions targeting antibiotic resistance.
Boston, Massachusetts, United States